Emily Torman, | |
2715 Lilac St, Longview, WA 98632-3526 | |
(360) 575-2775 | |
Not Available |
Full Name | Emily Torman |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 2715 Lilac St, Longview, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1386110898 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Emily Torman, 6446 N Commercial Ave, Portland, OR 97217-2025 Ph: () - | Emily Torman, 2715 Lilac St, Longview, WA 98632-3526 Ph: (360) 575-2775 |
News Archive
Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy.
Nutrient pollution, one of the greatest threats to our freshwater resources, is responsible for the algal blooms that blanket our lakes and waterways in summer months. Large blooms of cyanobacteria ('blue green algae') can cause fish kills, increase the cost of drinking water treatment, devalue shoreline properties, and pose health risks to people, pets, and wildlife. A new paper just published in the Canadian Journal of Fisheries and Aquatic Sciences shows that microcystin, a toxin produced by cyanobacteria, is present in Canadian lakes in every province.
Health companies have done better than the rest of corporate America during the past decade, MarketWatch/Seattle Times reports. While profits at the S&P 500 companies declined slightly over 10 years, "[d]ata compiled by MarketWatch show that the 52 health-care companies in the index are about to close out the decade with average profits that nearly tripled."
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Genetics researchers have identified a key gene that, when mutated, causes the rare multisystem disorder Cornelia deLange syndrome (CdLS). By revealing how mutations in the HDAC8 gene disrupt the biology of proteins that control both gene expression and cell division, the research sheds light on this disease, which causes intellectual disability, limb deformations and other disabilities resulting from impairments in early development.
› Verified 8 days ago
Dona Davis, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1619 20th Ave Apt 8, Longview, WA 98632 Phone: 360-575-1017 | |
Nancy Johnson, MSCCCSLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1500 3rd Ave, Longview, WA 98632 Phone: 360-423-8800 Fax: 360-423-6850 | |
Nancy Roseann D'urso, SLP-CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2715 Lilac St, Longview, WA 98632 Phone: 360-575-7000 | |
Joan Casciato Carpenter, M.A, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2715 Lilac St, Longview, WA 98632 Phone: 360-575-7000 | |
Julie Doherty, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1600 3rd Ave, Longview, WA 98632 Phone: 360-425-9810 | |
Rachel A Dille, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1600 3rd Ave, Longview, WA 98632 Phone: 360-425-9810 Fax: 360-425-1053 | |
Hilary S Allen, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1015 Ocean Beach Hwy Ste 16, Longview, WA 98632 Phone: 360-501-3750 |